casopitant + docetaxel

Casopitant + docetaxel is a combination of two pharmaceutical agents used primarily in the context of cancer therapy and supportive care. Docetaxel is a taxoid antineoplastic agent that promotes the assembly and stabilization of microtubules by binding to the β-subunit of tubulin, thereby inhibiting their depolymerization. This disrupts mitotic cell division and leads to apoptosis in rapidly dividing cancer cells[1][4][5]. Casopitant is a potent neurokinin-1 (NK1) receptor antagonist that acts centrally to block substance P-mediated emetic signaling pathways. It has been investigated for its antiemetic properties in chemotherapy-induced nausea and vomiting (CINV), particularly as an adjunct to regimens containing cytotoxic agents like docetaxel[7]. The combination has been studied for safety and pharmacokinetic interactions; coadministration does not significantly alter the pharmacokinetics or toxicity profile of docetaxel[3].